| # | Title | Journal | Year | Citations |
|---|
| 1 | Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer | JAMA Oncology | 2018 | 599 |
| 2 | Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers | Clinical Cancer Research | 2019 | 159 |
| 3 | Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33 | Human Molecular Genetics | 2014 | 90 |
| 4 | Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. | Journal of Clinical Oncology | 2021 | 69 |
| 5 | Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy | Clinical Cancer Research | 2015 | 61 |
| 6 | Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine | Frontiers in Microbiology | 2021 | 53 |
| 7 | Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors | Science Translational Medicine | 2020 | 51 |
| 8 | Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab | British Journal of Cancer | 2017 | 46 |
| 9 | Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS) | Annals of Oncology | 2017 | 45 |
| 10 | Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway | Clinical and Translational Oncology | 2011 | 44 |
| 11 | Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI) | Clinical and Translational Oncology | 2017 | 42 |
| 12 | Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry | European Journal of Surgical Oncology | 2018 | 42 |
| 13 | SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) | Clinical and Translational Oncology | 2020 | 41 |
| 14 | Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development | Cancer and Metastasis Reviews | 2015 | 39 |
| 15 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer | Clinical Cancer Research | 2021 | 36 |
| 16 | Treating KRAS-mutant NSCLC: latest evidence and clinical consequences | Therapeutic Advances in Medical Oncology | 2017 | 33 |
| 17 | 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial | Clinical Cancer Research | 2017 | 32 |
| 18 | FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial | ESMO Open | 2020 | 32 |
| 19 | SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) | Clinical and Translational Oncology | 2020 | 32 |
| 20 | MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC | Lung Cancer | 2012 | 31 |
| 21 | Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain | Psycho-Oncology | 2018 | 30 |
| 22 | Cost-minimisation analysis of three regimens of chemotherapy (docetaxel–cisplatin, paclitaxel–cisplatin, paclitaxel–carboplatin) for advanced non-small-cell lung cancer | Lung Cancer | 2002 | 25 |
| 23 | Seom guidelines for the treatment of gastric cancer 2015 | Clinical and Translational Oncology | 2015 | 25 |
| 24 | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy | PLoS ONE | 2014 | 24 |
| 25 | SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016) | Clinical and Translational Oncology | 2016 | 24 |
| 26 | Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer | Thrombosis and Haemostasis | 2019 | 24 |
| 27 | SEOM clinical guidelines for pancreatic and biliary tract cancer (2020) | Clinical and Translational Oncology | 2021 | 23 |
| 28 | Mammographic density and breast cancer in women from high risk families | Breast Cancer Research | 2015 | 22 |
| 29 | Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors | Oncologist | 2016 | 22 |
| 30 | Recent advances in genitourinary tumors: A review focused on biology and systemic treatment | Critical Reviews in Oncology/Hematology | 2017 | 22 |
| 31 | Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial | Breast Cancer Research | 2020 | 21 |
| 32 | Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer | Gastric Cancer | 2017 | 20 |
| 33 | Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy | Oncologist | 2019 | 20 |
| 34 | Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma | European Journal of Cancer | 2020 | 19 |
| 35 | Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium | Hereditary Cancer in Clinical Practice | 2022 | 19 |
| 36 | Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study) | Bone | 2014 | 18 |
| 37 | Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) | British Journal of Cancer | 2019 | 18 |
| 38 | Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy | Annals of Oncology | 2019 | 18 |
| 39 | Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry | Gastric Cancer | 2018 | 16 |
| 40 | A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer | Oncologist | 2019 | 16 |
| 41 | Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance | Biomedicines | 2021 | 16 |
| 42 | Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management | Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin | 2022 | 16 |
| 43 | Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment | Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin | 2022 | 16 |
| 44 | SEOM clinical guideline for treatment of kidney cancer (2017) | Clinical and Translational Oncology | 2018 | 15 |
| 45 | COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) | ESMO Open | 2022 | 15 |
| 46 | Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis | Journal of Geriatric Oncology | 2018 | 14 |
| 47 | An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer | Lung Cancer | 2019 | 14 |
| 48 | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry | PLoS ONE | 2020 | 14 |
| 49 | Menstrual and Reproductive Factors and Risk of Gastric and Colorectal Cancer in Spain | PLoS ONE | 2016 | 14 |
| 50 | Critically short telomeres and toxicity of chemotherapy in early breast cancer | Oncotarget | 2017 | 14 |
